Redmile Group’s Adverum Biotechnologies ADVM Stock Holding History

Redmile Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-2,224	Closed	-$264K	–	75
2019 Q2	$264K	Hold	2,224	–	–	0.01%	75
2019 Q1	$117K	Hold	2,224	–	–	﹤0.01%	80
2018 Q4	$70K	Hold	2,224	–	–	﹤0.01%	76
2018 Q3	$135K	Hold	2,224	–	–	﹤0.01%	82
2018 Q2	$118K	Hold	2,224	–	–	﹤0.01%	80
2018 Q1	$129K	Hold	2,224	–	–	0.01%	64
2017 Q4	$78K	Hold	2,224	–	–	﹤0.01%	69
2017 Q3	$81K	Hold	2,224	–	–	﹤0.01%	64
2017 Q2	$56K	Hold	2,224	–	–	﹤0.01%	63
2017 Q1	$60K	Hold	2,224	–	–	﹤0.01%	59
2016 Q4	$64K	Hold	2,224	–	–	0.01%	49
2016 Q3	$91K	Hold	2,224	–	–	0.01%	50
2016 Q2	$70K	Buy	+2,224	New	+$100K	0.01%	53
2016 Q1	–	Sell	-2,424	Closed	-$231K	–	48
2015 Q4	$231K	Sell	2,424 -72,418	-97%	-$6.36M	0.02%	54
2015 Q3	$6.17M	Buy	74,842 +21,114	+39%	+$2.7M	0.47%	38
2015 Q2	$8.72M	Buy	53,728 +11,615	+28%	+$3.92M	0.72%	37
2015 Q1	$17.1M	Sell	42,113 -27,794	-40%	-$11.7M	1.53%	25
2014 Q4	$37.8M	Sell	69,907 -39	-0.1%	-$15K	4.11%	9
2014 Q3	$21.5M	Buy	+69,946	New	+$20.8M	2.49%	15

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Redmile Group's ADVM Position: Q3 2019 in Review

Redmile Group sold out of Adverum Biotechnologies (ADVM) in Q3 2019, closing a stake of 2,224 shares — an estimated $264K sold.

Redmile Group first reported a position in ADVM in Q3 2014 and held it in 19 quarters. The position peaked at $37.8M in Q4 2014. 99 funds tracked by Wall St. Rank hold ADVM as of Q3 2019.

Redmile Group reported no remaining Adverum Biotechnologies position as of Q3 2019 after selling out during the quarter.
Redmile Group sold 2,224 Adverum Biotechnologies shares in Q3 2019, an estimated $264K.
Redmile Group first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 19 quarters.
Redmile Group's Adverum Biotechnologies position peaked at $37.8M in Q4 2014.
99 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2019.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.